In contrast, MYCN-amplified cell lines exhibited radioresistance under the same conditions, suggesting that targeting Gln metabolism can be beneficial for the treatment of c-MYC-driven but not MYCN-amplified neuroblastoma [134]. This evidence concerns the gene MYCN and neuroblastoma.